MENU
+Compare
NAMS
Stock ticker: NASDAQ
AS OF
Dec 26, 12:35 PM (EDT)
Price
$35.31
Change
-$0.34 (-0.95%)
Capitalization
4.04B

NAMS NewAmsterdam Pharma Company NV Forecast, Technical & Fundamental Analysis

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated... Show more

NAMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for NAMS with price predictions
Dec 24, 2025

NAMS in -2.30% downward trend, falling for three consecutive days on December 24, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NAMS declined for three days, in of 186 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for NAMS turned negative on December 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at .

NAMS moved below its 50-day moving average on December 15, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NAMS crossed bearishly below the 50-day moving average on December 11, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where NAMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 22, 2025. You may want to consider a long position or call options on NAMS as a result. In of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NAMS advanced for three days, in of 220 cases, the price rose further within the following month. The odds of a continued upward trend are .

NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NAMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.552) is normal, around the industry mean (26.541). P/E Ratio (0.000) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (114.943) is also within normal values, averaging (311.015).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
NAMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

NAMS is expected to report earnings to fall 34.21% to -40 cents per share on March 04

NewAmsterdam Pharma Company NV NAMS Stock Earnings Reports
Q4'25
Est.
$-0.40
Q3'25
Missed
by $0.21
Q2'25
Beat
by $0.34
Q1'25
Beat
by $0.16
Q4'24
Beat
by $0.03
The last earnings report on November 05 showed earnings per share of -61 cents, missing the estimate of -40 cents. With 310.43K shares outstanding, the current market capitalization sits at 4.04B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Gooimeer 2-35
Phone
+31 352062971
Employees
29
Web
https://www.newamsterdampharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RNNEX68.580.30
+0.44%
American Funds New Economy R2E
HIADX23.120.08
+0.35%
Hartford Dividend and Growth HLS IA
GMSMX20.380.06
+0.28%
GuideMark® Small/Mid Cap Core Service
SAMVX11.850.02
+0.17%
Virtus Ceredex Mid-Cap Value Equity A
TGWRX11.23N/A
N/A
Transamerica Large Growth R

NAMS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-0.83%
IDYA - NAMS
47%
Loosely correlated
+0.76%
IMVT - NAMS
46%
Loosely correlated
+0.45%
CRNX - NAMS
45%
Loosely correlated
-0.33%
ROIV - NAMS
43%
Loosely correlated
+0.22%
XENE - NAMS
41%
Loosely correlated
+1.06%
More